s nRNAs are among the most abundant and extensively studied RNAs in eukaryotes. These uridine (U)-rich noncoding RNAs, which include U1, U2, U4, U5, and U6, were discovered nearly fifty years ago 1 , and studies of their function lead to the elucidation of the fundamental molecular mechanisms that mediate pre-mRNA splicing 2, 3 . snRNAs undergo a series of processing events that are required for incorporation into spliceosomes. Except for U6 and U6atac snRNA 4 , snRNAs are synthesized by RNA polymerase II as precursors that initially contain a 3′-end extension and acquire an N -trimethylguanosine (TMG) cap, and the snRNA 3′ end is trimmed [7] [8] [9] . snRNAs incorporated into snRNPs are then transported back to the nucleus, where they assemble into spliceosomes that mediate pre-mRNA splicing [10] [11] [12] . snRNAs that are not properly processed do not get incorporated into snRNPs and are therefore unstable and degraded 13, 14 . Importantly, snRNAs contain a set of constitutive nucleotide modifications that are highly conserved across species and essential for snRNA integrity and function 15, 16 . Thus, all mature snRNAs are thought to exist as a single molecular species, and deviations outside of this species are not thought to be used by spliceosomes.
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, and studies of their function lead to the elucidation of the fundamental molecular mechanisms that mediate pre-mRNA splicing 2, 3 . snRNAs undergo a series of processing events that are required for incorporation into spliceosomes. Except for U6 and U6atac snRNA 4 , snRNAs are synthesized by RNA polymerase II as precursors that initially contain a 3′-end extension and acquire an N 7 -methylguanosine (m 7 G) cap 5 . snRNAs are exported into the cytosol, where they are incorporated into small nuclear ribonucleoproteins (snRNPs) by binding to Sm proteins 6 . Their m 7 G cap is then further methylated to form the N 2,2,7 -trimethylguanosine (TMG) cap, and the snRNA 3′ end is trimmed [7] [8] [9] . snRNAs incorporated into snRNPs are then transported back to the nucleus, where they assemble into spliceosomes that mediate pre-mRNA splicing [10] [11] [12] . snRNAs that are not properly processed do not get incorporated into snRNPs and are therefore unstable and degraded 13, 14 . Importantly, snRNAs contain a set of constitutive nucleotide modifications that are highly conserved across species and essential for snRNA integrity and function 15, 16 . Thus, all mature snRNAs are thought to exist as a single molecular species, and deviations outside of this species are not thought to be used by spliceosomes.
Recent data suggest that nucleotide modifications may be susceptible to demethylation reactions on the basis of studies of fat mass and obesity-associated protein (FTO) 17 . However, it has been difficult to identify endogenous substrates of FTO. FTO exhibits weak demethylase activity toward N ). Studies of FTO have primarily focused on mRNA. However, direct biochemical demonstration that a specific m 6 A or m 6 Am site in mRNA is regulated by FTO is missing. Because m 6 A and m 6 Am are present at high stoichiometry in mRNA, they appear to evade demethylation by FTO 19 . Indeed, nearly all the m 6 Am peaks in mRNA showed increases of less than 10% in the Fto-knockout brain compared to the wild type 19 . The moderate effect of FTO depletion on m 6 A or m 6 Am levels in mRNA likely reflects the fact that mRNAs are predominantly cytosolic 19 , whereas FTO is nuclear in most cells and tissues 17, 22 . Thus, we previously proposed that the endogenous target of FTO is likely to be nuclear RNA rather than mRNA 19 .
Here we show that all Sm-class spliceosomal snRNAs can exist as two distinct isoforms, differing by a single methyl modification on the adenosine residue that is located at the TSN of most snRNAs. This adenosine has previously been annotated to contain a constitutive 2′-O-methyl modification on the ribose sugar 15, 23 . We find that these adenosines are subjected to a second, reversible methylation selectively at the N 6 -position on the adenine base. This methylation converts the canonical single-methylated m 1 -snRNA to a dimethylated m 2 -snRNA. These m 2 -snRNAs are major targets of FTO, which functions early during snRNA biogenesis to convert the m 2 -snRNA back to m 1 -snRNA. FTO-mediated demethylation of m 2 -snRNA is blocked by the oncometabolite d-2-hydroxyglutarate, linking intracellular metabolism to snRNA methylation state. Upon FTO inhibition, m 2 -snRNAs accumulate and are assembled into snRNPs, and this correlated with enhanced splicing of exons that are normally poorly included. Overall, these data reveal the presence of an FTO-regulated methylation switch that enables the formation of previously unrecognized methyl isoforms of snRNA. Our findings identify m 6 Am in snRNAs as the major target of FTO and show the potential for FTO and cellular metabolites to influence transcriptome diversity by controlling the reversible methylation of snRNA.
Results
The RNA demethylase FTO selectively demethylates snRNAs. To identify FTO targets, we used the miCLIP approach, which involves N 6 -methyladenine (6mA) antibodies (which bind both m 6 A and m 6 Am) that are UV cross-linked to purified RNA. After stringent washing, we subjected antibody-bound RNA to next-generation sequencing to identify 6mA-modified nucleotides 24 . We used miCLIP to map 6mA in wild-type and Fto-knockout mouse liver RNA ( Supplementary Fig. 1a) . Unlike in previous studies 22, 25 , no poly(A) purification was used, thus allowing all cellular RNAs to be analyzed. To detect m 6 Am, we searched for RNA species that show increased methylation at the TSN in the Fto knockout transcriptome compared to wild type.
Although many RNAs showed potential methylation differences at the TSN (Fig. 1a , gray circles), the vast majority did not pass the applied filters, and their methylation change did not reach statistical significance after multiple-comparison testing. However, a small subset of methylation events was significantly increased in the Ftoknockout transcriptome (Fig. 1a , orange dots, adjusted P < 0.05). These RNAs were exclusively small nuclear RNAs (snRNAs), including U1, U4atac, and U5. In each case, the miCLIP signal was associated with read terminations at the TSN, suggesting that the first nucleotide contains an N 6 -methyl modification. We next looked at the methylation fold change of Sm-class and Lsmclass snRNAs. We observed increased TSN methylation of all Sm-class snRNAs of the major and minor spliceosome ( Fig. 1b; Supplementary  Fig. 1b) . In each case, the 6mA reads were detected around the TSN and were between 10-20-fold higher in the Fto-knockout compared to wild-type snRNAs ( Fig. 1c; Supplementary Fig. 2a-h ).
In addition to snRNAs, several snRNA-like transcripts showed markedly increased 6mA reads in the Fto-knockout transcriptome. These include U7, which is involved in 3′-end processing of histone mRNAs 26 , and the small nucleolar RNAs (snoRNAs) U3 and U8, which function in rRNA processing ( Supplementary Fig. 3a-c ). U3 and U8 snoRNAs are unusual in that they are not derived from intronic sequences, but instead are transcribed from their own gene by RNA polymerase II using a promoter that contains sequence elements typical for snRNA genes 27 . No other snoRNAs exhibited significantly elevated 6mA reads in the Fto knockout.
The increase in 6mA reads was seen in all Sm-class snRNAs, but not in Lsm-class snRNAs U6 and U6atac-the only two spliceosomal snRNAs that are transcribed by RNA polymerase III 4 ( Fig. 1b . Nevertheless, and in contrast to a recent report 29 , FTO depletion did not lead to a statistically significant alteration in 6mA reads at this internal position ( Supplementary Figs. 2g and 4a) .
Similarly, U2, which contains an internal m 6 Am (ref.
15
; see also https://modomics.genesilico.pl), did not show a robust increase of 6mA reads at this position ( Supplementary Fig. 2a) . Notably, U1 snRNA, which is thought to lack m 6 A or m 6 Am at internal sites based on 6mA immunoprecipitation experiments and biochemical modification mapping 28, 30, 31 , was recently suggested to contain m 6 Am at a previously undocumented internal site 29 . However, no significant enrichment of miCLIP reads was detected at this site in Fto-knockout liver (Supplementary Fig. 4b ). miCLIP does not distinguish between mature snRNA and the unprocessed longer snRNA precursors or truncated forms. Therefore, we used 6mA immunoblotting to detect the length of 6mA-immunoreactive snRNAs. In these experiments, we immunoblotted small RNA (<200 nt) from wild-type and FTO-knockout HEK293 cells. We observed bands corresponding to the mature snRNA forms, with significantly increased 6mA immunoreactivity in FTO-knockout cells (Fig. 1d) .
Overall, the miCLIP results indicate that the FTO-regulated sites are specifically localized to the TSN region of Sm-class snRNAs, and all Sm-class snRNAs are substrates for FTO-mediated demethylation.
The first nucleotide of snRNAs is reversibly methylated. The finding that Sm-class snRNA modification is regulated by FTO was surprising, as these snRNAs are not known to contain m 6 Am or m 6 A at the TSN. Instead, Sm-class snRNAs are thought to contain Am at this position 8 . As the miCLIP results suggest that the first nucleotide in snRNAs in FTO-knockout cells is either m 6 A or m 6 Am, we determined its identity using a thin-layer chromatography (TLC)-based assay 21 . In this assay, the 5′ cap is removed, and the exposed 5′ nucleotide is then radiolabeled with [γ-32 P]ATP. Next, the snRNAs are treated with RNase P1, and the nucleotide hydrolysate is resolved by 2D-TLC. This approach readily identifies the first nucleotide on the basis of its migration pattern 21 . We first examined the small RNA fraction (<200 nt), which is highly enriched in snRNAs. In wild-type cells, the first nucleotide was predominantly Am, with low, but measurable levels of m 6 Am (Fig. 2a) . However, small RNAs prepared from FTO-knockout HEK293 cells exhibited a pronounced increase in the level of m 6 Am at the first nucleotide (Fig. 2a) .
We next directly measured the first nucleotide in gel-purified U1 and U2, which migrate to well-defined positions by PAGE (Figs. 1d and 2b,c). Consistent with previous publications 8 , the first nucleotide in U1 and U2 was predominantly Am in wild-type HEK293 cells (Fig. 2b,c) . However, in FTO-knockout cells, m 6 Am was markedly increased to levels similar to Am (Fig. 2b,c) .
U2 is difficult to analyze by miCLIP because it contains a constitutive internal m 6 Am, which causes this snRNA to be immunoprecipitated irrespective of the methylation status of its TSN ( Supplementary Fig. 2a ). The TLC analysis directly demonstrates that U2 also contains an m 6 Am nucleotide that is regulated by FTO (Fig. 2c) .
We next developed a MS-based assay to examine m 6 Am or Am specifically in the context of the cap structure. Small RNA was treated with P1 nuclease, which resulted in digestion of all internal nucleotides to mononucleotides. Under these conditions, the first nucleotide remains connected to the cap in the form of a 'cap-dinucleotide' structure (cap-ppp-Am or cap-ppp-m 6 Am; Supplementary Fig. 5a ). Cap-dinucleotides were readily quantified by high-resolution mass spectrometry (HR-MS) using positive-ion-mode detection, as negative-ion mode did not allow sensitive detection ( Supplementary  Fig. 5b) . A multiple-reaction monitoring protocol was developed based on the fragment ion transitions from distinct dinucleotide precursor species (Supplementary Fig. 5c ). This approach exhibited high sensitivity and linear detection of cap dinucleotides, thus revealing the first nucleotide within the cap context ( Supplementary Fig. 5d ).
We verified that Am was associated with the cap after digestion of small RNA from wild-type HEK293 cells (Fig. 2d) . However, m 6 Am was the predominant form in FTO-knockout HEK293 cells, with a 6.3-fold enrichment of m 6 Am over Am (Fig. 2d) . Thus, both TLC and MS indicate that snRNAs contain m 6 Am at the first nucleotide in FTO-deficient cells.
Together, these results suggest that during snRNA biogenesis, snRNAs undergo methylation to form a readily detectable ) compared to wildtype (WT) liver. Transcripts with significant upregulation (P ≤ 0.05) of transcription-start nucleotide (TSN) methylation are indicated in orange (data represent average from datasets of three independent biological replicates per genotype). b, FTO deficiency leads to increased TSN methylation of major spliceosomal snRNAs. The mean log 2 fold-change in TSN methylation of specific snRNA gene classes (U1, U2, U4, U5 and U6) in Fto −/− mouse liver compared to WT is shown (data represents average from data sets of three independent biological replicates per genotype; each box shows the first quartile, median, and third quartile; whiskers represent 1.5× interquartile ranges; one-way ANOVA with Tukey's post hoc test, ***P ≤ 0.001). c, U1 snRNA shows increased TSN methylation in FTO-deficient mouse liver. Grey tracks denote WT liver; blue tracks denote Fto −/− liver. A representative read coverage track for U1 snRNA is shown (RPM, reads per million mapped reads; data represent combined tracks from datasets of three independent biological replicates per genotype). d, FTO deficiency leads to increased methylation of mature snRNAs. 6mA-immunoblot of WT and FTO −/− HEK293 cells. Methylation of U1, U2, and U6 snRNAs was detected with an antibody directed against 6mA. The left panel shows a representative 6mA immunoblot with positions of nucleotide size markers and individual snRNAs indicated on the left and right, respectively. The right panel shows the quantification of 6mA signal in U1 and U2 snRNA relative to the 6mA signal in U6 snRNA (n = 3 independent biological replicates; mean ± s.e.m.; unpaired Student's t-test; ***P ≤ 0.001).
MS from various cells and tissues. In brain, only m 1 -snRNAs were detected (Fig. 2e) . However, in liver, HEK293 cells, mouse embryonic stem cells (mESCs), HT1080 fibrosarcoma and TF-1 erythroleukemia cells, m 2 -snRNAs were readily detected at 1-15% of the level of m 1 -snRNAs ( Fig. 2e ; Supplementary Fig. 6b -e). UOK262 renal cell carcinoma cells, which exhibit elevated fumarate because of fumarate hydratase deficiency 32 , showed a ~3-fold higher m 2 -snRNA-to-m 1 -snRNA ratio than HEK293 cells ( Supplementary Fig. 6c ).
We next asked whether the levels of m 1 -snRNAs and m 2 -snRNAs are regulated during embryonic stem cell development. To test this, we cultured mESCs for 5 d in the presence or absence of differentiation inhibitors. MS revealed a two-fold increase in m 2 -snRNAs upon removal of differentiation inhibitors ( Supplementary Fig. 6d,e) .
Together, these data indicate that m 2 -snRNAs are nearly undetectable in many cells and tissues but can be readily detected in others and can be induced in response to certain stimuli. . In control cells, m 1 -snRNAs predominated as the first major nucleotide in small RNA. However, m 2 -snRNAs were markedly elevated following expression of both IDH1 R132H and IDH2
R140Q
, in proportion to the increase in intracellular 2-HG levels ( Fig. 3a-c; Supplementary Fig. 7a,b) . Notably, this effect was blocked by mutant isoform-selective small-molecule inhibitors, indicating that the formation of m 2 -snRNAs in 2-HG-dependent pathogenic conditions is reversible ( Fig. 3a-c ; Supplementary Fig. 7a,b) .
We also tested the effects of dimethylfumarate, a prodrug that is converted to fumarate in cells. Treatment of HEK293 cells for 7 d with 70 µM dimethylfumarate, a concentration used to study the cellular effects of this compound 38 , did not significantly affect m 2 -snRNA levels ( Supplementary Fig. 7c ). Thus, dimethylfumarate is unlikely to mediate its clinical effects by increasing levels of m 2 -snRNAs.
Taken together, these data indicate that m 2 -snRNA levels can be altered by 2-HG and suggest the possibility that 2-HG-dependent pathogenic conditions are associated with increased levels of m 2 -snRNAs.
Am is demethylated before cap hypermethylation. snRNAs biogenesis involves an initial nuclear phase, in which snRNAs contain an m 7 G cap, and a second nuclear phase, which occurs after cytoplasmic processing and is marked by the presence of a TMG cap on snRNAs 7 . Because FTO is predominantly nuclear 17 , the conver- Am not detected; n = 3 independent biological replicates, mean ± s.d.; unpaired Student's t-test, **P < 0.01).
sion of m 2 -snRNAs to m 1 -snRNAs by FTO likely takes place during one of these two nuclear phases.
We therefore chemically synthesized RNA substrates mimicking the pre-export and post-import cap structure of snRNA. These 20-nt-long RNAs started with either an m 7 G or a TMG cap, which was followed by a triphosphate linker and m (Fig. 4a) . However, FTO did not detectably demethylate m 6 Am when using the post-import RNA substrate comprising m 6 Am with a TMG cap (Fig. 4a) . These data suggest that m 2 -snRNAs are not a substrate for FTO after TMG-cap formation.
Based on the m 7 G cap-specific demethylation, and considering the nuclear localization of FTO, we infer that the decision to demethylate m 2 -snRNAs and form m 1 -snRNAs is determined during the initial nuclear phase, after snRNA transcription but before cytoplasmic formation of the TMG cap and assembly of snRNPs. m 2 -snRNAs acquire a TMG cap and assemble into snRNPs. To test whether m 2 -snRNAs assemble into snRNPs, we immunoprecipitated snRNPs from cellular extracts using a small ribonucleoprotein particle protein B (SmB)-specific antibody. This approach has previously been shown to immunoprecipitate assembled snRNPs 39, 40 . We then determined the first nucleotide of snRNAs in cellular snRNPs to see whether m 2 -snRNAs are present. As expected, in wild-type HEK293 cells m 1 -snRNAs were predominant (Fig. 4b) . However, in FTO-knockout HEK293 cells m 2 -snRNAs were readily detected (Fig. 4b) . Thus, m 2 -snRNAs form a distinct m 6 Am-containing class of snRNPs, that is, m 2 -snRNPs.
After snRNAs are incorporated into snRNPs, their m 7 G cap is modified to form the TMG cap 9 . We asked whether m 2 -snRNAs are similarly methylated to form the TMG cap using MS. The small RNA fraction was purified from FTO-knockout HEK293 cells and Fto-knockout mouse liver and brain. The RNA was digested with nuclease P1 to liberate the cap and m Taken together, these data show that m 2 -snRNAs undergo normal biogenesis, including incorporation into snRNPs and acquisition of the TMG cap structure.
Altered splicing is associated with m 2 -snRNAs. We next sought to examine splicing changes upon FTO depletion. Similarly to a previous study 41 , we found that the most pronounced effect of FTO deficiency is increased exon inclusion (Supplementary Fig. 8a ). To further refine this analysis, we characterized the included exons for binding sites of known splicing factors in a previously published Am) to m 1 -snRNA caps (Am) represented by the integrated peak area ratio of the MRM transition. Blocking production of 2-HG by specific inhibition of mutant IDH1 and IDH2 isoforms with AGI-5027 and AGI-6780, respectively, shows that these effects are reversible (n = 3 independent biological replicates, mean ± s.d.; one-way ANOVA with Tukey's post hoc test *P ≤ 0.05, **P ≤ 0.01).
RNA-seq analysis using control and FTO-knockout HEK293 cells 42 .
Here, we observed a significant and specific enrichment for SRSF1, HNRNPH2 and HNRNPK-dependent exons but did not detect enrichment of other exons ( Supplementary Figs. 8b and 9a) . Similar effects were also seen in our HEK293T FTO-knockdown RNA-seq dataset ( Supplementary Fig. 9b ). Thus, FTO depletion is associated with enhanced inclusion of exons that would normally be inefficiently spliced into mature mRNA.
We next wanted to determine how m 6 Am affects snRNAs and whether any of these changes are consistent with altered splicing phenotypes. In the case of mRNAs, DCP2-mediated mRNA degradation is impaired when m 6 Am is present at the first nucleotide 19 . However, northern blotting of cellular RNA harvested from DCP2-knockout HEK293 cells, which primarily contain m 1 -snRNAs, showed no increase in snRNAs relative to wild-type cells (Supplementary Fig. 10a ). Thus, DCP2 does not appear to regulate m 1 -snRNAs.
When we examined our own and pre-existing 42 RNA-seq datasets from FTO-depleted cells, we observed moderately increased levels of some (for example, U1, U4, and U5), but not all, Sm-class snRNA transcripts ( Supplementary Fig. 10b-f) .
Surprisingly, many genes encoding Lsm-class snRNAs (that is, U6 and U6atac) showed increased expression ( Supplementary Fig. 10b,c) . U6 and U6atac lack m 6 Am, as they do not have adenosine at the first transcribed nucleotide, and show no alteration in 6mA levels in their transcript body in FTO-knockout cells based on miCLIP ( Supplementary Fig. 2g,h ). Although U6 and U6atac do not contain m 6 Am, they assemble into multiple distinct complexes with FTO-regulated Sm-class snRNPs. The increase in U6 snRNA levels in FTO-deficient cells may therefore be the consequence of altered interactions of U6 with m 2 -snRNPs compared to m 1 -snRNPs.
Overall, these data demonstrate that FTO deficiency indirectly increases levels of U6, which could therefore impact splicing.
Discussion
A major class of cellular noncoding RNA are the snRNAs, which get assembled into ribonucleoproteins and have central roles in RNA processing reactions such as pre-mRNA splicing. Although snRNAs are often regulated by trans-acting splicing factors that modulate the association of snRNPs to specific transcripts, the modified nucleotides in snRNAs have not previously been thought to be the target of regulation. Here we show that snRNAs contain a regulated nucleotide methylation switch that allows them to exist as either of the two distinct methylation isoforms. This methyl modification is located at the adenosine of the first encoded nucleotide in mRNA, is reversible, and is correlated with enhanced snRNA abundance and altered splicing profiles in cells. Together, our studies provide evidence that reversible epitranscriptomic information is encoded at the first nucleotide of snRNAs and that the reversible and regulated methylation of this nucleotide by FTO is a key aspect of snRNA biogenesis.
Our study focused on snRNA biogenesis and identified the formation of m 2 -snRNA and its subsequent demethylation to m 1 -snRNA as a previously unknown step in snRNA maturation ( Supplementary Fig. 11 ). snRNA biogenesis was extensively studied and involves Sm core assembly, 3′ processing, nucleotide modifications at internal sites, and formation of the hypermethylated guanosine cap 6, [9] [10] [11] [12] 15 . Although Sm-class snRNAs were known to contain a 2′-O-methyl modification at the evolutionarily conserved starting adenosine, our data reveal that snRNA biogenesis also involves a previously unrecognized N 6 -methylation of this nucleotide. We find that the N 6 -methyl modification is subsequently removed by FTO, thus converting m 2 -snRNAs to m 1 -snRNAs. Our studies reveal that FTO is an snRNA biogenesis factor and snRNA biogenesis involves reversible methylation of the extended snRNA cap.
Our studies shed light on the physiologic substrate of FTO. Previous studies have focused on mRNA, and it has been argued that the high levels of m 6 A may make it a relevant substrate for FTO despite the weak demethylation activity observed for m . However, any relevant substrate for FTO should in fact be low in abundance or undetectable, not high in abundance, in FTO-expressing cells. Indeed, m 6 Am in snRNA meets this criteria. We show that m 6 Am is very low in abundance in snRNA in most cells until FTO depletion. Given the high levels of snRNA in cells, the total cellular levels of m 6 Am are markedly increased upon FTO depletion. Unlike m 6 Am, whose stoichiometry was directly quantified in specific snRNAs, m 6 A has not been similarly shown to be regulated by FTO at any specific site by quantitative biochemical measurements of m 6 A stoichiometry. Without this data, it remains unclear whether FTO can directly demethylate specific m 6 A residues in mRNA at a meaningful level. As no m 6 A or m 6 Am sites in mRNA show statistically significant increases in miCLIP signals upon depletion of FTO, our data suggest that FTO does not substantially affect the methylation state of these nucleotides in mRNA.
FTO was previously shown to influence alternative splicing. These splicing changes were initially attributed to FTO-regulated m 6 A residues around splice sites. However, a role for m 6 A in alternative splicing has recently been challenged 45 . Our findings potentially provide a resolution by showing that FTO regulates m 6 Am in spliceosomal snRNAs. Thus, our discovery of FTO-regulated m 2 -snRNAs provides the first direct link between FTO activity and the mRNA splicing machinery.
The decision to demethylate the m 2 -snRNA appears to be determined early in snRNA biogenesis. We find that FTO-mediated demethylation of m 2 -snRNAs is inhibited when 2-HG levels are increased because of expression of a cancer-associated mutant IDH. FTO was previously shown to be inhibited by metabolites that compete with α-ketoglutarate, including citrate, succinate, fumarate and 2-HG 33, 34 . Our studies raise the possibility that 2-HG and potentially other metabolite abnormalities may mediate their effects, in part, by inhibiting FTO and increasing the levels of m 2 -snRNAs that could in turn influence specific snRNA-mediated mRNA processing or splicing events.
The presence of m 2 -snRNAs is not restricted to cells that lack FTO or express mutant IDH. We also detected m 2 -snRNAs in mouse embryonic stem cells, TF-1 cells, and mouse liver tissue by miCLIP and MS. It will be important to determine the full spectrum of cell-type-specific regulation of m 2 -snRNA expression in vivo and establish whether different levels of m 2 -snRNAs accumulate in cells because of FTO inhibition or due to other mechanisms.
How does the N 6 -methyl modification affect the fate of snRNA? The N 6 -methyl modification is unlikely to affect snRNA:pre-mRNA hybridization steps because these hybrids occur mostly at internal sites in the snRNA. For example, U1 snRNA hybridizes to the 5′ splice site using nucleotides 3-7 (ref.
46
). Instead, the methyl modification may affect the interactions of snRNA with other complexes. Splicing involves dynamic assembly and disassembly of U6 and U6atac snRNPs with Sm-class snRNPs 47 . It is intriguing to speculate that the altered U6 levels reflect differences in the dynamics of m 1 -snRNP and m 2 -snRNP complex assembly with U6. This may be mediated by dedicated reader proteins that alter the overall assembly, disassembly, or turnover of multi-m 2 -snRNP complexes. These alterations may in turn account for the increase in U6 snRNA levels. Therefore, it will be important to monitor the dynamics of multim 1 -and m 2 -snRNP complexes and to determine the transcriptomewide binding properties of m 2 -snRNPs.
Notably, recent studies have shown that the levels of individual types of snRNAs can have large effects on splicing efficiency 48 , and reduced snRNA expression is associated with severe splicing abnormalities 44, 49 . The increased expression of U6 and some Sm-class snRNAs associated with FTO deficiency may influence splicing patterns by specifically promoting the inclusion of exons that are otherwise inefficiently spliced due to rate-limiting availability of individual snRNPs or their higher order snRNP complexes.
Although snRNAs were previously thought to be comprised of a single molecular species, the demonstration that snRNAs exist as distinct methyl isoforms indicates a potential regulatory role for methylation switches in splicing. Importantly, some snRNAs have nonsplicing functions 26, 50 , and their m 2 -isoforms are likely to influence other RNA processing pathways. We suspect phenotypes linked to altered expression of FTO reflect alterations in these diverse snRNA-regulated RNA processing pathways. More research will be needed to understand the diversity of RNA processing alterations associated with m 2 -snRNAs.
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Crystal structure of human spliceosomal U1 snRNP at 5. To analyze 6mA coverage at the transcription-start nucleotide (TSN) and internal sites, the following steps were carried out. Input and miCLIP reads were aligned to mm10 with STAR to generate RPM-normalized bedgraphs and sorted bam files 51 (version 2.5.2a;). Bedgraphs were visualized using the Integrative Genomics Viewer 52 (IGV, version 2.4.4). Sorted bam files were converted to bed format, and read coverage was determined in a 20-nucleotide window flanking annotated TSN (UCSC) or a 4-nucleotide window flanking the internal site of interest using bedtools (version 2.25.0). miCLIP TSN coverage reads were then counted and normalized to input coverage reads using the Deseq2 pipeline 53 (version 1.18.1; commands: design = ~assay + condition + assay:condition; test = "LRT", reduced = ~assay + condition). Analysis and visualization was carried out with custom in-house generated R-scripts using RStudio (Version 1.0.136). Only transcripts with normalized read counts >10 were included in the analyses.
For all other RNA-seq analyses, total RNA was diluted to a concentration of 50 ng/µL, and libraries were prepared using the Illumina TruSeq Stranded mRNA Library Prep Kit (RS-122-2101, Illumina). The libraries were sequenced in pairedend mode with 100 bases per read. At least two independent biological replicates were sequenced for each condition.
Previously published RNA-seq datasets used in the current study (GSE79577,  GSE78040) 19,42 were extracted from Gene Expression Omnibus (GEO, NCBI).
Cell culture and animals. Flp-In T-REx HEK293 cells (R78007, Thermo Fisher Scientific) and DCP2-knockout (DCP2 −/− ) HEK293 cells 19 were maintained in DMEM (Thermo Fisher Scientific) with 10% FBS and antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin) under standard tissue culture conditions. Control, IDH1 R132H and IDH2 R140Q TF-1 erythroleukemia cells were generated and maintained as previously described 36 . Intracellular 2-hydroxyglutarate concentrations were determined as previously described 36 . To inhibit production of neomorphic 2-hydroxyglutarate, IDH1
R132H cells or IDH2 R140Q cells were treated for 7 d with 1 µM AGI-5027 (SML1298, Sigma-Aldrich) or AGI-6780 (SML0895, Sigma-Aldrich), respectively.
Naive mouse embryonic stem cells (mESCs) were maintained in Knockout DMEM (Thermo Fisher Scientific) with 15% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, 2 mM l-glutamine, 50 µM β-mercaptoethanol (Thermo Fisher Scientific), nonessential amino acids (Thermo Fisher Scientific), recombinant mouse LIF (EMD Millipore), GSK3 inhibitor (04000402, Stemgent) and MEK1 inhibitor (04000602, Stemgent) under standard tissue culture conditions. To induce differentiation, naive mESCs were deprived of LIF, GSK3 inhibitor and MEK1 inhibitor for 7 d.
Only Antibodies used were as follows. For western blot analysis mouse anti-FTO (ab92821, Abcam) and mouse anti-ACTB (A2228, Sigma) were used. For 6mA-immunoprecipitation/miCLIP, rabbit anti-6mA (202-003, Synaptic Systems) was used. For SmB-IP, a previously described mouse abti-SmB antibody (clone 18F6) was used. For 6mA immunoblotting, a rabbit anti-6mA antibody (ab190886, Abcam) was used.
Validation
Validation of antibody specificity was done using knockout samples or by making a dilution curve of the respective antigen.
